Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | EYA2 | O00167 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10783976 | 0.79 | TDP1 (0.36) | TDP1EYA2APPACELMNA | |
| SCHEMBL7124418 | 0.77 | TDP1 (0.43) | TDP1EYA2APPACELMNA | |
| SCHEMBL4586640 | 0.76 | TDP1 (0.38) | TDP1EYA2APPACELMNA | |
| SCHEMBL28980823 | 0.72 | EGLN1 (0.41) | TDP1EYA2APPACELMNA | |
| SCHEMBL10808296 | 0.70 | LMNA (0.33) | TDP1LMNATSHRCHRM2FFAR3 | |
| SCHEMBL6243323 | 0.69 | TDP1 (0.47) | TDP1EYA2APPACELMNA | |
| Ethylenediamine SCHEMBL29281297 | 0.69 | GLRA1 (0.36) | TDP1EYA2APPACELMNA | |
| Nitrilotriacetic Acid SCHEMBL7038304 | 0.67 | TDP1 (0.61) | TDP1EYA2APPACELMNA | |
| SCHEMBL21955799 | 0.65 | GLRA1 (0.39) | TDP1EYA2APPACELMNA | |
| SCHEMBL7430219 | 0.65 | TDP1 (0.38) | TDP1EYA2APPACELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 535 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | UNIV RAMOT (IL) | 2026-05-07 | — | — | US | claimed |
| EP-4712983-A1 | AGENTS TO GENERATE REPAIR OLIGODENDROCYTES AND THEIR USE FOR AXONAL REGROWTH | Johannes Gutenberg-Universität Mainz (DE) | 2026-03-25 | — | — | EP | claimed |
| US-20260027096-A1 | PHD INHIBITORS | UNIV OXFORD INNOVATION LTD (GB) | 2026-01-29 | — | — | US | claimed |
| EP-4661861-A1 | USE OF HIF-1A STABILIZING AGENTS FOR THE TREATMENT OF TYPE I INTERFERONOPATHIES | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-12-17 | — | — | EP | claimed |
| EP-4655288-A1 | PHD INHIBITORS | Oxford University Innovation Limited (GB) | 2025-12-03 | — | — | EP | claimed |
| EP-4603578-A1 | ENGINEERED RED BLOOD CELLS AND METHOD OF PRODUCTION THEREOF | DRK-Blutspendedienst Nord-Ost gGmbH (DE) | 2025-08-20 | — | — | EP | claimed |
| US-20250250538-A1 | METHODS FOR MAKING AND USING DIFFERENTIATED NEURAL CELLS | RESEARCH DEVELOPMENT FOUNDATION (US) | 2025-08-07 | — | — | US | claimed |
| WO-2025120597-A1 | SECRETOME-BASED BIOMATERIAL, METHOD FOR ITS PRODUCTION AND USES THEREOF | UNIVERSIDADE DE AVEIRO (PT) | 2025-06-12 | — | — | WO | claimed |
| US-12319740-B2 | Methods for production of tissue resident memory-like T cells and use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-06-03 | — | — | US | claimed |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2025-04-24 | — | — | US | claimed |
| WO-2009149026-A9 | GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS | TUFTS MEDICAL CENTER, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100016434-A1 | Inhibitors of Egln3 Activity for the Treatment of Neurodegenerative Disorders | KAELIN JR WILLIAM G | 2010-01-21 | — | — | US | claimed |
| WO-2009149026-A2 | GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS | TUFTS MEDICAL CENTER, INC. (US) | 2009-12-10 | — | — | WO | claimed |
| WO-2009067790-A1 | STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION | UTI LIMITED PARTNERSHIP (CA) | 2009-06-04 | — | — | WO | claimed |
| WO-2008157177-A1 | METHODS FOR MODULATING OSTEOBLAST CELL DIFFERENTIATION AND BONE GENERATION THROUGH INHIBITION OF A PROLYL HYDROXYLASE | THE UAB RESEARCH FOUNDATION (US) | 2008-12-24 | — | — | WO | claimed |
| EP-1912637-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2008-04-23 | — | — | EP | claimed |
| WO-2007009044-A2 | INHIBITORS OF EGLN3 ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | DANA FARBER CANCER INSTITUTE, INC. (US) | 2007-01-18 | — | — | WO | claimed |
| US-20040146964-A1 | hydroxylases which act on hypoxia inducible factor alpha (HIF- alpha ) and which are involved in the regulation of the cellular turnover of HIF | ISIS INNOVATION LIMITED (GB) | 2004-07-29 | — | — | US | claimed |
| EP-1379630-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LIMITED (GB) | 2004-01-14 | — | — | EP | claimed |
| WO-2002074981-A2 | ASSAYS, METHODS AND MEANS RELATING TO HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | ISIS INNOVATION LTD. (GB) | 2002-09-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124274-A1 | METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON | RNMT, TRMT1L, UPF1 | TDP1 1143/4885EYA2 1343/4885APP 1465/4885 |
| US-20250129170-A1 | EPO RECEPTOR AGONISTS AND ANTAGONISTS | EPOR, MPL, PRLHR | TDP1 4846/4885EYA2 2657/4885APP 3975/4885 |
| US-20260027096-A1 | PHD INHIBITORS | HIF1AN, HIF1A, EGLN1 | TDP1 3901/4885EYA2 2427/4885APP 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.